The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance
- 1 August 1993
- journal article
- Published by Elsevier in Metabolism
- Vol. 42 (8), 945-949
- https://doi.org/10.1016/0026-0495(93)90005-9
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Elevated fibrinogen and plasminogen activator inhibitor (PAI‐1) in hypertension are related to metabolic risk factors for cardiovascular diseaseJournal of Internal Medicine, 1990
- Tissue Plasminogen Activator Inhibition in Diabetes MellitusDiabetes Care, 1989
- INSULIN DEFICIENCY IN NON-INSULIN-DEPENDENT DIABETESThe Lancet, 1989
- Banting lecture 1988. Role of insulin resistance in human diseaseDiabetes, 1988
- Impaired fibrinolysis in coronary artery diseaseAmerican Heart Journal, 1988
- Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1988
- PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTIONThe Lancet, 1987
- On the Usefulness of Fibrinolysis Variables in the Characterization of a Risk Group for Myocardial ReinfarctionActa Medica Scandinavica, 1987
- Increased Plasma Levels of a Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial InfarctionNew England Journal of Medicine, 1985
- Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution.Journal of Clinical Investigation, 1983